China NT Pharma (01011) Publishes Monthly Return for 30 November 2025

Bulletin Express

Dec 01, 2025

China NT Pharma Group Company Limited (01011) released its monthly return for 30 November 2025. According to the document, the total authorised share capital remained unchanged at USD 50,100. This includes 62,592,500,000 authorised ordinary shares at a par value of USD 0.0000008 (amounting to USD 50,074) and 32,500,000 preference shares at the same par value (amounting to USD 26).

The number of issued ordinary shares stood at 674,246,015, with no change from the prior month and no treasury shares recorded. The report noted no arrangements or agreements for share issuance, and no outstanding share options, warrants, or convertible instruments. The submission confirmed compliance with relevant listing rules and legal requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1114798820"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1114798820\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1114798820?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 17:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114798820","market":"hk","top_or_hot":-1,"title":"China NT Pharma (01011) Publishes Monthly Return for 30 November 2025","media":"Bulletin Express","content":"<p>China NT Pharma Group Company Limited (01011) released its monthly return for 30 November 2025. According to the document, the total authorised share capital remained unchanged at USD 50,100. This includes 62,592,500,000 authorised ordinary shares at a par value of USD 0.0000008 (amounting to USD 50,074) and 32,500,000 preference shares at the same par value (amounting to USD 26).</p>\n<p>The number of issued ordinary shares stood at 674,246,015, with no change from the prior month and no treasury shares recorded. The report noted no arrangements or agreements for share issuance, and no outstanding share options, warrants, or convertible instruments. The submission confirmed compliance with relevant listing rules and legal requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China NT Pharma (01011) Publishes Monthly Return for 30 November 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina NT Pharma (01011) Publishes Monthly Return for 30 November 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-12-01 17:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China NT Pharma Group Company Limited (01011) released its monthly return for 30 November 2025. According to the document, the total authorised share capital remained unchanged at USD 50,100. This includes 62,592,500,000 authorised ordinary shares at a par value of USD 0.0000008 (amounting to USD 50,074) and 32,500,000 preference shares at the same par value (amounting to USD 26).</p>\n<p>The number of issued ordinary shares stood at 674,246,015, with no change from the prior month and no treasury shares recorded. The report noted no arrangements or agreements for share issuance, and no outstanding share options, warrants, or convertible instruments. The submission confirmed compliance with relevant listing rules and legal requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01011","symbol_name":"泰凌医药","start_time":0,"source_url":"","article_id":"1114798820","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114798820","pubTimestamp":1764582254,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China NT Pharma Group Company Limited (01011) released its monthly return for 30 November 2025. According to the document, the total authorised share capital remained unchanged at USD 50,100. This...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01011":"泰凌医药"},"translate_title":"泰凌医药(01011)公布2025年11月30日月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01011":1},"content_text":"China NT Pharma Group Company Limited (01011) released its monthly return for 30 November 2025. According to the document, the total authorised share capital remained unchanged at USD 50,100. This includes 62,592,500,000 authorised ordinary shares at a par value of USD 0.0000008 (amounting to USD 50,074) and 32,500,000 preference shares at the same par value (amounting to USD 26).\nThe number of issued ordinary shares stood at 674,246,015, with no change from the prior month and no treasury shares recorded. The report noted no arrangements or agreements for share issuance, and no outstanding share options, warrants, or convertible instruments. The submission confirmed compliance with relevant listing rules and legal requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}